PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway
Jian Zhou(Sun Yat-sen University), Chunxue Bai(Fudan University)
Cited by 51
Related Papers
Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study
|The Lancet|2018|1.7k
Prevalence, risk factors, and management of asthma in China: a national cross-sectional study
|The Lancet|2019|759
Bone marrow‐derived mesenchymal stem cells enhance autophagy <i>via </i><scp>PI</scp>3K/<scp>AKT</scp> signalling to reduce the severity of ischaemia/reperfusion‐induced lung injury
|Journal of Cellular and Molecular Medicine|2015|64
Heterogeneities and impact profiles of early chronic obstructive pulmonary disease status: findings from the China Pulmonary Health Study
|The Lancet Regional Health - Western Pacific|2024|45
Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway
|Journal of Experimental & Clinical Cancer Research|2019|41